News & Updates
Showing Rheumatology articles
Showing
Show Multimedia Only

Dostarlimab plus chemo prolongs survival in advanced dMMR/MSI-H endometrial cancer
02 Jul 2026
byStephen Padilla
Treatment with dostarlimab combined with carboplatin and paclitaxel (CP) confers sustained long-term progression-free survival (PFS) and overall survival (OS) benefits on patients with primary advanced or recurrent deficient mismatch repair and microsatellite instability-high (dMMR/MSI-H) endometrial cancer, as shown by the results of the phase III RUBY trial.
02 Jul 2026







